Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
Pharmaceutical giant Roche has entered into a collaboration with Syapse to widen access to precision oncology technology and services.
The partners aim to develop jointly-branded clinical decision support software for faster, more accurate, and more confident decision-making.
The company also expects to report a 31 percent increase in full-year 2017 revenues.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.
Horizon will develop NTRK fusion immunohistochemistry reference standards to be used in oncology assays.
Labs reported on their work with kits from both Roche and Thermo Fisher, both of which have launched new commercial liquid biopsy products in recent years.
Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.
The New York Times reports on the shifting interpretations of what some genetic variants mean over time.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.